JMR-132

**JMR-132** is a synthetic peptide antagonist of growth hormone-releasing hormone (GHRH) developed as an experimental anti-cancer agent. Its primary mechanism is inhibition of tumoral GHRH signaling, acting via high-affinity binding to splice variants of GHRH receptors (notably SV1) on tumor cells. This leads to suppression of downstream proliferative and anti-apoptotic signaling pathways, notably PI3K/Akt/mTOR and Raf/MEK/ERK, resulting in cell cycle arrest (in S-phase) and induction of apoptosis. Preclinical data demonstrate significant inhibition of tumor growth in in vitro and in vivo models of colon, prostate, and breast cancers, both as monotherapy and additively in combination with S-phase-specific cytotoxic agents (e.g., 5-FU, irinotecan, cisplatin, docetaxel). JMR-132 is not approved for clinical use and remains an investigational compound in oncology research[1][3][4][6][7].